Similarly, GLP-1 RAs have been shown to significantly reduce poor cardiovascular and renal outcomes among diabetic patients with established cardiovascular disease, as demonstrated in the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes-6 (SUSTAIN-6, ClinicalTrials.gov number NCT01720446) and Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER, ClinicalTrials.gov number NCT01179048) trials [11,12]. This evidence concerns the gene GCG and type 2 diabetes mellitus.